Talk:Guduchi - Revision history

Agnivesha at 10:22, 13 April 2026

2026-04-13T10:22:10Z

← Older revision		Revision as of 10:22, 13 April 2026
Line 1:		Line 1:
	Guduchi (Tinospora cordifolia (WILLD.) HOOK.F. & THOMS.)		Guduchi (Tinospora cordifolia (WILLD.) HOOK.F. & THOMS.)

	''Guduchi'' (~~{{langx\|sa\|~~गुडूची}}), commonly known as [[Giloy]], is the Sanskrit name for the medicinal plant [[Tinospora cordifolia]] (Willd.) Hook. f. & Thomson of the family [[Menispermaceae]].<ref name="AYUSHDossier">{{Cite web \|url=https://ayush.gov.in/resources/pdf/quality_standards/guduchi_Book-Dossier.pdf \|title=Technical Dossier on - Guduchi \|format=PDF \|publisher=Ministry of AYUSH, Government of India \|year=2019 \|access-date=2026-04-13}}</ref> It holds a prominent place in [[Ayurveda]] as a [[Rasayana]] (rejuvenative) herb and is widely used for conditions such as fever, jaundice, musculoskeletal disorders, skin diseases, and metabolic ailments.<ref name="AYUSHDossier"/>		''Guduchi'' (गुडूची), commonly known as ' Giloy', is the Sanskrit name for the medicinal plant Tinospora cordifolia (Willd.) Hook. f. & Thomson of the family [[Menispermaceae]].<ref name="AYUSHDossier">{{Cite web \|url=https://ayush.gov.in/resources/pdf/quality_standards/guduchi_Book-Dossier.pdf \|title=Technical Dossier on - Guduchi \|format=PDF \|publisher=Ministry of AYUSH, Government of India \|year=2019 \|access-date=2026-04-13}}</ref> It holds a prominent place in [[Ayurveda]] as a [[Rasayana]] (rejuvenative) herb and is widely used for conditions such as fever, jaundice, musculoskeletal disorders, skin diseases, and metabolic ailments.<ref name="AYUSHDossier"/>


Line 15:		Line 15:
	\|data4 = Available		\|data4 = Available
	\|label5 = Contributors		\|label5 = Contributors
	\|data5 = --		\|data5 = Deole Y.S.
	\|label6 = Year of publication		\|label6 = Year of publication
	\|data6 = 2026		\|data6 = 2026

Agnivesha: /* Current research trends */

2026-04-13T10:17:30Z

Current research trends

← Older revision		Revision as of 10:17, 13 April 2026
Line 486:		Line 486:
	== Current research trends ==		== Current research trends ==

	PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest.~~<ref name="IMRReview2020"/>,~~<ref name="AYUSHDossier"/> This growth reflects heightened scientific and public interest but does not, by itself, equate to high‑quality clinical evidence.<ref name="MetabolicReview2025"/>		PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest.<ref name="AYUSHDossier"/> This growth reflects heightened scientific and public interest but does not, by itself, equate to high‑quality clinical evidence.<ref name="MetabolicReview2025"/>

	Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025~~"/>,<ref name="IMRReview2020~~"/>		Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025"/>

	== Clinical position ==		== Clinical position ==

Agnivesha: /* Clinical position */

2026-04-13T10:14:57Z

Clinical position

← Older revision		Revision as of 10:14, 13 April 2026
Line 492:		Line 492:
	== Clinical position ==		== Clinical position ==

	From an Ayurvedic perspective, Guduchi is regarded as a classical Rasayana with broad therapeutic indications, supported by long‑standing clinical experience.<ref name="AYUSHDossier"/><ref name="OnePlantManyRoles"/> From a modern evidence‑based medicine standpoint, it is best viewed as a promising but not yet fully established botanical agent for conditions such as metabolic syndrome, certain inflammatory disorders, and liver and immune‑mediated conditions.<ref name="MetabolicReview2025~~"/><ref name="IMRReview2020~~"/>		From an Ayurvedic perspective, Guduchi is regarded as a classical Rasayana with broad therapeutic indications, supported by long‑standing clinical experience.<ref name="AYUSHDossier"/><ref name="OnePlantManyRoles"/> From a modern evidence‑based medicine standpoint, it is best viewed as a promising but not yet fully established botanical agent for conditions such as metabolic syndrome, certain inflammatory disorders, and liver and immune‑mediated conditions.<ref name="MetabolicReview2025"/>

	Use in clinical practice should emphasize:<ref name="LiverTox"/><ref name="AYUSHDossier"/>		Use in clinical practice should emphasize:<ref name="LiverTox"/><ref name="AYUSHDossier"/>

Agnivesha: /* Current research trends */

2026-04-13T10:10:57Z

Current research trends

← Older revision		Revision as of 10:10, 13 April 2026
Line 486:		Line 486:
	== Current research trends ==		== Current research trends ==

	PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest.<ref name="IMRReview2020"/><ref name="AYUSHDossier"/> This growth reflects heightened scientific and public interest but does not, by itself, equate to high‑quality clinical evidence.<ref name="MetabolicReview2025"/>		PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest.<ref name="IMRReview2020"/>,<ref name="AYUSHDossier"/> This growth reflects heightened scientific and public interest but does not, by itself, equate to high‑quality clinical evidence.<ref name="MetabolicReview2025"/>

	Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025"/><ref name="IMRReview2020"/>		Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025"/>,<ref name="IMRReview2020"/>

	== Clinical position ==		== Clinical position ==

Agnivesha: /* Safety and hepatotoxicity */

2026-04-13T10:05:09Z

Safety and hepatotoxicity

← Older revision		Revision as of 10:05, 13 April 2026
Line 478:		Line 478:
	== Safety and hepatotoxicity ==		== Safety and hepatotoxicity ==

	In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="LiverInjury2023">{{Cite journal\|last=Nnamani \|first=I. \|year=2023 \|title=Tinospora cordifolia (Guduchi/Giloy)‑induced liver injury \|journal=BMJ Case Reports\|volume=16 \|issue=11 \|pages=e254123 \|doi=10.1136/bcr‑2023‑254123 \|pmid=37273324}}</ref>,<ref name="PMC2021LiverInjury">Björnsson ES, Navarro VJ, Chalasani N. Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, or de novo AIH? J Clin Exp Hepatol. 2022 Jan-Feb;12(1):6-9. doi: 10.1016/j.jceh.2021.11.014. Epub 2021 Nov 29. PMID: 35068778; PMCID: PMC8766689.</ref>		In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="PMC2021LiverInjury">Björnsson ES, Navarro VJ, Chalasani N. Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, or de novo AIH? J Clin Exp Hepatol. 2022 Jan-Feb;12(1):6-9. doi: 10.1016/j.jceh.2021.11.014. Epub 2021 Nov 29. PMID: 35068778; PMCID: PMC8766689.</ref>

	The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox~~"/>,<ref name="LiverInjury2023~~"/>		The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/>

	The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/>		The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/>

Agnivesha: /* Safety and hepatotoxicity */

2026-04-13T10:02:28Z

Safety and hepatotoxicity

← Older revision		Revision as of 10:02, 13 April 2026
Line 478:		Line 478:
	== Safety and hepatotoxicity ==		== Safety and hepatotoxicity ==

	In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="LiverInjury2023">{{Cite journal\|last=Nnamani \|first=I. \|year=2023 \|title=Tinospora cordifolia (Guduchi/Giloy)‑induced liver injury \|journal=BMJ Case Reports \|volume=16 \|issue=11 \|pages=e254123 \|doi=10.1136/bcr‑2023‑254123 \|pmid=37273324}}</ref><ref name="PMC2021LiverInjury">~~{{Cite journal \|year=2021 \|title=~~Liver ~~injury following~~ Tinospora ~~cordifolia consumption~~: ~~a case series \|journal=International Journal of General Medicine \|volume=14 \|pages=11131–11137 \|~~doi=10.~~2147~~/~~IJGM~~.~~S345678 \|pmcid=~~PMC8766689}}</ref>		In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="LiverInjury2023">{{Cite journal\|last=Nnamani \|first=I. \|year=2023 \|title=Tinospora cordifolia (Guduchi/Giloy)‑induced liver injury \|journal=BMJ Case Reports\|volume=16 \|issue=11 \|pages=e254123 \|doi=10.1136/bcr‑2023‑254123 \|pmid=37273324}}</ref>,<ref name="PMC2021LiverInjury">Björnsson ES, Navarro VJ, Chalasani N. Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, or de novo AIH? J Clin Exp Hepatol. 2022 Jan-Feb;12(1):6-9. doi: 10.1016/j.jceh.2021.11.014. Epub 2021 Nov 29. PMID: 35068778; PMCID: PMC8766689.</ref>

	The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/>,<ref name="LiverInjury2023"/>		The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/>,<ref name="LiverInjury2023"/>

Agnivesha: /* Chemical constituents */

2026-04-13T09:59:43Z

Chemical constituents

← Older revision		Revision as of 09:59, 13 April 2026
Line 444:		Line 444:
	== Chemical constituents ==		== Chemical constituents ==

	Modern phytochemical studies have identified more than 200 compounds in ''Tinospora cordifolia'' and related species, including diterpenoids, alkaloids, glycosides, steroids, sesquiterpenoids, and phenolics.<ref name="ImmunomodulatoryReview">Yates CR, Bruno EJ, Yates MED. Tinospora Cordifolia: A review of its immunomodulatory properties. J Diet Suppl. 2022;19(2):271-285. doi: 10.1080/19390211.2021.1873214. Epub 2021 Jan 22. PMID: 33480818.</ref> Key constituents reported in the literature include:<ref name="AYUSHDossier"/>,<ref name="OnePlantManyRoles">{{Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012 Apr;31(4):151-9. doi: 10.4103/0257-7941.107344. PMID: 23661861; PMCID: PMC3644751</ref>		Modern phytochemical studies have identified more than 200 compounds in ''Tinospora cordifolia'' and related species, including diterpenoids, alkaloids, glycosides, steroids, sesquiterpenoids, and phenolics.<ref name="ImmunomodulatoryReview">Yates CR, Bruno EJ, Yates MED. Tinospora Cordifolia: A review of its immunomodulatory properties. J Diet Suppl. 2022;19(2):271-285. doi: 10.1080/19390211.2021.1873214. Epub 2021 Jan 22. PMID: 33480818.</ref> Key constituents reported in the literature include:<ref name="AYUSHDossier"/>,<ref name="OnePlantManyRoles">Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012 Apr;31(4):151-9. doi: 10.4103/0257-7941.107344. PMID: 23661861; PMCID: PMC3644751</ref>

	* Clerodane‑type diterpenoids		* Clerodane‑type diterpenoids

Agnivesha: /* Chemical constituents */

2026-04-13T09:59:12Z

Chemical constituents

← Older revision		Revision as of 09:59, 13 April 2026
Line 444:		Line 444:
	== Chemical constituents ==		== Chemical constituents ==

	Modern phytochemical studies have identified more than 200 compounds in ''Tinospora cordifolia'' and related species, including diterpenoids, alkaloids, glycosides, steroids, sesquiterpenoids, and phenolics.<ref name="ImmunomodulatoryReview">{{Yates CR, Bruno EJ, Yates MED. Tinospora Cordifolia: A review of its immunomodulatory properties. J Diet Suppl. 2022;19(2):271-285. doi: 10.1080/19390211.2021.1873214. Epub 2021 Jan 22. PMID: 33480818.}}</ref> Key constituents reported in the literature include:<ref name="AYUSHDossier"/><ref name="OnePlantManyRoles">{{Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012 Apr;31(4):151-9. doi: 10.4103/0257-7941.107344. PMID: 23661861; PMCID: PMC3644751}}</ref>		Modern phytochemical studies have identified more than 200 compounds in ''Tinospora cordifolia'' and related species, including diterpenoids, alkaloids, glycosides, steroids, sesquiterpenoids, and phenolics.<ref name="ImmunomodulatoryReview">Yates CR, Bruno EJ, Yates MED. Tinospora Cordifolia: A review of its immunomodulatory properties. J Diet Suppl. 2022;19(2):271-285. doi: 10.1080/19390211.2021.1873214. Epub 2021 Jan 22. PMID: 33480818.</ref> Key constituents reported in the literature include:<ref name="AYUSHDossier"/>,<ref name="OnePlantManyRoles">{{Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012 Apr;31(4):151-9. doi: 10.4103/0257-7941.107344. PMID: 23661861; PMCID: PMC3644751</ref>

	* Clerodane‑type diterpenoids		* Clerodane‑type diterpenoids

Agnivesha: /* References */

2026-04-13T09:57:24Z

References

← Older revision		Revision as of 09:57, 13 April 2026
Line 509:		Line 509:

	==References==		==References==

	~~<references>~~
	<ref name="AYUSHDossier">{{Cite web \|url=https://ayush.gov.in/resources/pdf/quality_standards/guduchi_Book-Dossier.pdf \|title=Technical Dossier on - Guduchi \|format=PDF \|publisher=Ministry of AYUSH, Government of India \|year=2019 \|access-date=2026-04-13}}</ref>
	<ref name="LiverTox">{{Cite web \|url=https://www.ncbi.nlm.nih.gov/books/NBK608429/ \|title=Tinospora – LiverTox \|publisher=National Center for Biotechnology Information, NIH \|year=2025 \|access-date=2026-04-13}}</ref>
	<ref name="IMRReview2020">{{Cite journal \|year=2020 \|title=Tinospora cordifolia: a review of its immunomodulatory, anti‑inflammatory and other pharmacological activities \|journal=Integrative Medicine Research \|volume=9 \|issue=4 \|pages=e100553 \|doi=10.1016/j.imr.2020.100553 \|pmid=33480818}}</ref>
	<ref name="MetabolicReview2025">{{Cite journal \|year=2025 \|title=Effects of Tinospora cordifolia (giloy) on metabolic syndrome components: a mechanistic review \|journal=Naunyn‑Schmiedeberg's Archives of Pharmacology \|volume=398 \|issue=5 \|pages=4979–5009 \|doi=10.1007/s00210‑024‑03642‑2 \|pmid=39731594}}</ref>
	<ref name="Arthritis2015">{{Cite journal \|last=Sannegowda \|first=K. M. \|year=2015 \|title=Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage \|journal=International Journal of Immunopathology and Pharmacology \|volume=28 \|issue=4 \|pages=521–531 \|doi=10.1177/0394632015608248 \|pmid=26467057}}</ref>
	<ref name="OnePlantManyRoles">{{Cite journal \|last=Kumar \|first=Rajeev \|title=Tinospora cordifolia: One plant, many roles \|journal=Journal of Clinical and Diagnostic Research \|volume=6 \|issue=5 \|pages=857–860 \|year=2012 \|pmid=23136574}}</ref>
	<ref name="ScientificReports2019">{{Cite journal \|year=2019 \|title=Tinospora cordifolia protects against inflammation in a murine model of alcohol‑induced liver injury \|journal=Scientific Reports \|volume=9 \|issue=1 \|pages=10574 \|doi=10.1038/s41598‑019‑47458‑0 \|pmid=31

Agnivesha: /* Safety and hepatotoxicity */

2026-04-13T09:56:48Z

Safety and hepatotoxicity

← Older revision		Revision as of 09:56, 13 April 2026
Line 478:		Line 478:
	== Safety and hepatotoxicity ==		== Safety and hepatotoxicity ==

	In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/><ref name="LiverInjury2023">{{Cite journal \|last=Nnamani \|first=I. \|year=2023 \|title=Tinospora cordifolia (Guduchi/Giloy)‑induced liver injury \|journal=BMJ Case Reports \|volume=16 \|issue=11 \|pages=e254123 \|doi=10.1136/bcr‑2023‑254123 \|pmid=37273324}}</ref><ref name="PMC2021LiverInjury">{{Cite journal \|year=2021 \|title=Liver injury following Tinospora cordifolia consumption: a case series \|journal=International Journal of General Medicine \|volume=14 \|pages=11131–11137 \|doi=10.2147/IJGM.S345678 \|pmcid=PMC8766689}}</ref>		In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="LiverInjury2023">{{Cite journal\|last=Nnamani \|first=I. \|year=2023 \|title=Tinospora cordifolia (Guduchi/Giloy)‑induced liver injury \|journal=BMJ Case Reports \|volume=16 \|issue=11 \|pages=e254123 \|doi=10.1136/bcr‑2023‑254123 \|pmid=37273324}}</ref><ref name="PMC2021LiverInjury">{{Cite journal \|year=2021 \|title=Liver injury following Tinospora cordifolia consumption: a case series \|journal=International Journal of General Medicine \|volume=14 \|pages=11131–11137 \|doi=10.2147/IJGM.S345678 \|pmcid=PMC8766689}}</ref>

	The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/><ref name="LiverInjury2023"/>		The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/>,<ref name="LiverInjury2023"/>

	The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/>		The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/>